1-9 of 9
Edward Allan R. Sison
Close
Sort by
Journal Articles

Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL- rearranged ( MLL- R) Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Amos S. Gaikwad, PhD, Gaye Jenkins, Terzah M. Horton, MD PhD, Patrick Brown, MD, Michele S. Redell, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1585.
https://doi.org/10.1182/blood.V128.22.1585.1585
Published: 2016
Journal Articles

A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment

Michael J Krueger, BS, Matthew Minus, BS, Wei Liu, PhD, Xin Long, PhD, Alexandra M. Stevens, MD, Mikhail I. Kolosov, BS, Edward Allan R. Sison, MD, David John Tweardy, MD, Zachary T. Ball, PhD, Michele S. Redell, MD PhD
Journal: Blood
Blood (2015) 126 (23): 569.
https://doi.org/10.1182/blood.V126.23.569.569
Published: 2015
Journal Articles

POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, BS, Li Li, PhD, Barbara Romagnoli, PhD, Garry Douglas, PhD, Gerald Tuffin, PharmD/PhD, Johann Zimmermann, PhD, Patrick Brown, MD
Journal: Blood
Blood (2014) 124 (21): 3707.
https://doi.org/10.1182/blood.V124.21.3707.3707
Published: 2014
Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD
Journal: Blood
Blood (2013) 122 (21): 2680.
https://doi.org/10.1182/blood.V122.21.2680.2680
Published: 2013
Journal Articles

Extended Exposure To The CXCR4 Inhibitor Plerixafor May Lead To Enhanced Microenvironment Interactions in Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, Patrick Brown, MD
Journal: Blood
Blood (2013) 122 (21): 1295.
https://doi.org/10.1182/blood.V122.21.1295.1295
Published: 2013
Journal Articles

The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, Eric Chevalier, PhD, Klaus Dembowsky, MD, PhD, Patrick Brown, MD
Journal: Blood
Blood (2012) 120 (21): 780.
https://doi.org/10.1182/blood.V120.21.780.780
Published: 2012
Journal Articles

Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects

Colleen E. Annesley, MD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Edward Allan R. Sison, MD, David Loeb, MD, PhD, Patrick A. Brown, MD
Journal: Blood
Blood (2011) 118 (21): 2437.
https://doi.org/10.1182/blood.V118.21.2437.2437
Published: 2011
Journal Articles

Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia

Edward Allan R. Sison, MD, Daniel Magoon, Li Li, PhD, Rachel E. Rau, MD, Colleen E. Annesley, MD, Donald Small, MD, PhD, Patrick A. Brown, MD
Journal: Blood
Blood (2011) 118 (21): 1410.
https://doi.org/10.1182/blood.V118.21.1410.1410
Published: 2011
Journal Articles

Upregulation of Surface CXCR4 In Response to Chemotherapy Confers a Stromal-Mediated Survival Advantage In Acute Leukemia

Edward Allan R. Sison, MD, Emily McIntyre, Daniel Magoon, Patrick Brown, MD
Journal: Blood
Blood (2010) 116 (21): 2734.
https://doi.org/10.1182/blood.V116.21.2734.2734
Published: 2010